{"product_id":"mayo-clinic-integrating-pharmacogenomics-into-clinical-practice-certificate-program-2022-videos-assessment-quiz","title":"Mayo Clinic Integrating Pharmacogenomics into Clinical Practice: Certificate Program 2022 (Videos + Assessment Quiz)","description":"\u003ch3\u003eMayo Clinic Integrating Pharmacogenomics into Clinical Practice: Certificate Program 2022 (Videos + Assessment Quiz)\u003c\/h3\u003e\n\u003cp\u003ePharmacogenomics (PGx) is the study of how one’s genes may affect an individual’s response to medication and is an emerging field within patient care. Mayo Clinic experts have created an online certificate program on how to integrate PGx into clinical practice for pharmacists, physicians, nurse practitioners, physician assistants, nurses \u0026amp; students.\u003c\/p\u003e\n\u003cdiv id=\"tab-description\" class=\"woocommerce-Tabs-panel woocommerce-Tabs-panel--description panel entry-content active\" role=\"tabpanel\" aria-labelledby=\"tab-title-description\"\u003e\n\u003cdiv class=\"prod-desc\"\u003e\n\u003cdiv class=\"field field-name-field-course-summary field-type-text-with-summary field-label-hidden\"\u003e\n\u003cdiv class=\"field-items\"\u003e\n\u003cdiv class=\"field-item even\"\u003e\n\u003cp\u003eLearners enrolled in this course will enjoy over 16 hours of engaging content, including case studies and over 50 videos that can be reviewed at their own pace, anytime. Earn a certificate of completion and CME credit in the process.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"group-target-audience field-group-div\"\u003e\n\u003cp\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"field field-name-field-target-audience field-type-text-long field-label-hidden\"\u003e\n\u003cdiv class=\"field-items\"\u003e\n\u003cdiv class=\"field-item even\"\u003e\n\u003cp\u003eThis activity has been designed for pharmacists, physicians, nurse practitioners, physician assistants, nurses, students, and other members of the healthcare team.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"group-learning-objectives field-group-div\"\u003e\n\u003cp\u003e\u003cstrong\u003eLearning Objectives\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"field field-name-field-learning-objectives field-type-text-long field-label-hidden\"\u003e\n\u003cdiv class=\"field-items\"\u003e\n\u003cdiv class=\"field-item even\"\u003e\n\u003cp\u003eUpon completion of this activity, participants should be able to:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReview foundational pharmacogenomics principles.\u003c\/li\u003e\n\u003cli\u003eDescribe what to consider when implementing pharmacogenomics in clinical practice.\u003c\/li\u003e\n\u003cli\u003eApply pharmacogenomics test results to make recommendations for an individualized medication management plan.\u003c\/li\u003e\n\u003cli\u003eIdentify barriers and challenges of considering pharmacogenomics in patient care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAttendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eProgram : \u003c\/strong\u003e\u003c\/p\u003e\n\u003ch4\u003eIntegrating Pharmacogenomics into Clinical Practice\u003c\/h4\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics (PGx) Principles and Concepts\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics 101: An Introduction to Foundational Concepts\u003c\/u\u003e\u003cbr\u003e\nChristopher T. Grilli, Pharm.D., R.Ph., M.B.A.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eVariability and Pharmacokinetic Principles\u003c\/u\u003e\u003cbr\u003e\nWayne T. Nicholson, M.D., Pharm.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eSex, Drugs, and Genetic Variation\u003c\/u\u003e\u003cbr\u003e\nAnn M. Moyer, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics’ Emerging Role\u003c\/u\u003e\u003cbr\u003e\nRichard Weinshilboum, M.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics: Discovery and Translation\u003c\/u\u003e\u003cbr\u003e\nLiewei Wang, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eUntangling the Polypharmacy Burden with Pharmacogenomics Testing\u003c\/u\u003e\u003cbr\u003e\nEric T. Matey, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics (PGx) Rules and Regulations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003eLegal Implications of Pharmacogenomics Testing\u003c\/u\u003e\u003cbr\u003e\nSharon C. Zehe, J.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003ePGx from a Patient Perspective: GINA \u0026amp; Other Important Questions\u003c\/u\u003e\u003cbr\u003e\nTeresa M. Kruisselbrink, M.S., CGC, LCGC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics (PGx) Clinical Laboratory Testing\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003eClinical Laboratory Testing in PGx: “the Lab” 101\u003c\/u\u003e\u003cbr\u003e\nAnn M. Moyer, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eClinical Laboratory Testing in PGx: Targeting Genotyping Technology\u003c\/u\u003e\u003cbr\u003e\nAnn M. Moyer, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eClinical Laboratory Testing in PGx: “Sequencing”\u003c\/u\u003e\u003cbr\u003e\nAnn M. Moyer, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eClinical Laboratory testing in PGx: “Reporting”\u003c\/u\u003e\u003cbr\u003e\nAnn M. Moyer, M.D., Ph.D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics in Practice: General Principles\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics Testing: Role in Clinical Medicine\u003c\/u\u003e\u003cbr\u003e\nDenise M. Dupras, M.D., Ph.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003e10 Considerations for the Clinician Applying Pharmacogenomics to Practice\u003c\/u\u003e\u003cbr\u003e\nWayne T. Nicholson, M.D., Pharm.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003ePolypharmacy and PGx: Multi-Drug, Herbal\/Dietary Supplement Case Study\u003c\/u\u003e\u003cbr\u003e\nMichael J. Schuh, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eUtilizing National Pharmacogenomics Guidelines and Other Resources\u003c\/u\u003e\u003cbr\u003e\nJessica A. Wright, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eCase Review: From My Practice to Yours\u003c\/u\u003e\u003cbr\u003e\nSheena K. Crosby, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics in Practice: Panel Discussions\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics from the Patient Perspective\u003c\/u\u003e\u003cbr\u003e\nDarryl S. Chutka, M.D. (Moderator), Matthew J. Ferber, Ph.D., Karen M. Meagher, Ph.D. \u0026amp; Sharon C. Zehe, J.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics from the Clinician Perspective\u003c\/u\u003e\u003cbr\u003e\nMatthew E. Bernard, M.D., Jennifer A. Bold APRN, C.N.P., D.N.P., Darryl S. Chutka, M.D. (Moderator) \u0026amp; Paul Y. Takahashi, M.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics from the Pharmacy Perspective\u003c\/u\u003e\u003cbr\u003e\nChristopher Grilli, Pharm.D., R.Ph.,M.B.A. (Moderator), Ashley D. Ebenhoh, Pharm.D., R.Ph., \u0026amp; Razan M. El Melik, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eEducation for the Multidisciplinary Team\u003c\/u\u003e\u003cbr\u003e\nJyothsna (Jo) Giri, M.D., M.B.A., Christopher M. Kohler, M.A.N., R.N., N.E.-B.C., Tammy M. McAllister, M.A. (Moderator), \u0026amp; Lance J. Oyen, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics in Practice: Analgesic\/Anesthesia\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics of Analgesics\u003c\/u\u003e\u003cbr\u003e\nWayne (Nick) T. Nicholson, M.D., Pharm.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics: Anesthesia\u003c\/u\u003e\u003cbr\u003e\nTimothy B. Curry, M.D., Ph.D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics in Practice: Psychiatry\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics of Antidepressants\u003c\/u\u003e\u003cbr\u003e\nAdrijana Kekic, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eCase Review: Antidepressants, SSRIs (Sertraline) and SNRIs\u003c\/u\u003e\u003cbr\u003e\nAdrijana Kekic, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003ePsychiatric Pharmacogenomics: Panel Discussion\u003c\/u\u003e\u003cbr\u003e\nDarryl S. Chutka, M.D. (Moderator), Eric T. Matey, Pharm.D., R.Ph., Denise M. Dupras, M.D., Ph.D., Richard Weinshilboum, M.D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics in Practice: Cardiology\/GI\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics in Cardiovascular Disease\u003c\/u\u003e\u003cbr\u003e\nNaveen L. Pereira, M.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eWarfarin \u0026amp; Statin Pharmacogenomics Cases\u003c\/u\u003e\u003cbr\u003e\nJan A. Anderson, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003ePGx use in Patients with Gastroesophageal Reflux Disease\u003c\/u\u003e\u003cbr\u003e\nImad Absah, M.D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics in Practice: Oncology\/Hematology\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics in Oncology\u003c\/u\u003e\u003cbr\u003e\nEric J. Yancey, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eWhy is CYP2D6 Genotyping Ready for Primetime: Association of CYP2D6 Genotype and Breast Cancer Outcome from Large Trials\u003c\/u\u003e\u003cbr\u003e\nMatthew P. Goetz, M.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eDihydropyrimidine Dehydrogenase (DPD) Deficiency: Implications for 5-Fluorouracil (Capecitabine) Treatment\u003c\/u\u003e\u003cbr\u003e\nRobert B. Diasio, M.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eBelinostat and UGT1A Polymorphism\u003c\/u\u003e\u003cbr\u003e\nN. Nora Bennani, M.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eCase: Oncology\u003c\/u\u003e\u003cbr\u003e\nCaren L. Hughes, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eCase Study: Thiopurines\/TPMT and NUDT15 in Clinical Practice\u003c\/u\u003e\u003cbr\u003e\nEdward V. Loftus, Jr. M.D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics in Practice: Transplant, Infectious Disease, Immunology, Urology\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics for Transplant Patients: Immunosuppression and Beyond\u003c\/u\u003e\u003cbr\u003e\nMira T. Keddis, M.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003ePharmacogenomics: Challenges with Hematopoietic Stem Cell and Liver Transplantation\u003c\/u\u003e\u003cbr\u003e\nJohn Logan Black, M.D.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eVoriconazole Case\u003c\/u\u003e\u003cbr\u003e\nChristopher J. Arendt, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eUsing Pharmacogenomics to Predict Drug Hypersensitivity\u003c\/u\u003e\u003cbr\u003e\nJohn D. Zeuli, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eHLA and Hypersensitivity\u003c\/u\u003e\u003cbr\u003e\nJyothsna (Jo) Giri, M.D., M.B.A.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eGout Management: Role of Pharmacogenomics\u003c\/u\u003e\u003cbr\u003e\nDenise M. Dupras, M.D., Ph.D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacogenomics Implementation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cu\u003eSignificant Pharmacogenomics Cases\u003c\/u\u003e\u003cbr\u003e\nHeather H. Randles, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003cli\u003e\n\u003cu\u003eDeveloping an Individualized Medication Plan\u003c\/u\u003e\u003cbr\u003e\nEric T. Matey, Pharm.D., R.Ph.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n","brand":"My Store","offers":[{"title":"Default Title","offer_id":42954578722914,"sku":"MED-AMB06509","price":45.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Mayo-Clinic-Integrating-Pharmacogenomics-into-Clinical-Practice-Certificate-Program-2022.jpg?v=1779380101","url":"https:\/\/meducourse.com\/products\/mayo-clinic-integrating-pharmacogenomics-into-clinical-practice-certificate-program-2022-videos-assessment-quiz","provider":"Meducourse","version":"1.0","type":"link"}